Onego Bio
Onego Bio is a Precision Fermentation company founded in 2022 and based in Helsinki, Finland. It has raised $70.8M in total funding, most recently a Series A in 2024.
Spun out of Finland's VTT Technical Research Centre in 2022, Onego Bio was co-founded by CEO Maija Itkonen, CTO Chris Landowski and COO Jussi Joensuu to produce egg-white protein through precision fermentation. Its product, Bioalbumen, is a bioidentical ovalbumin, the primary protein in egg white, made by engineering the fungus Trichoderma reesei to secrete the protein, claimed to reproduce egg white's foaming, gelling and binding functions without chickens. The company raised a $40 million Series A in 2024, bringing reported funding to roughly $70.8 million, and in September 2025 the FDA issued a 'no questions' letter on its GRAS determination, clearing Bioalbumen for use across food categories in the US. Onego Bio is headquartered in Helsinki, Finland.
An FDA-cleared, fermentation-made egg-white protein arriving as avian flu and egg-price volatility push food makers toward animal-free egg ingredients.
onego.bio ↗·Precision Fermentation·
Finland·private 
